Contact: Katie Glenn, firstname.lastname@example.org, 202-375-6472
WASHINGTON (Aug 16, 2017) -
Physicians identified a majority of patients with advanced heart failure as at high risk for transplant, left ventricular assist device (LVAD) or death while few of those patients considered themselves to be at high risk, according to a study published today in JACC: Heart Failure.
Physicians rated 161 patients for perceived risk for transplant, LVAD or death in the upcoming year. The patients were also surveyed about their perceptions of their life expectancy and willingness to undergo different treatment options.
Sixty-nine percent of the patients were considered at high risk for transplant, LVAD or death by their physicians. However, only 14 percent of patients considered themselves to be at high risk. Over 13 months of follow-up, 38 percent of patients experienced an endpoint: 21 percent deaths, 8 percent transplants and 9 percent LVAD implants.
"It was surprising that there were such drastic differences between patient perceptions and physician perceptions of heart failure disease severity," said Amrut V. Ambardekar, MD, an assistant professor in the division of cardiology at the University of Colorado and the study's lead author. "We hope better understanding these differences will facilitate improved patient-physician communication regarding advanced heart failure therapies."
Researchers also assessed patient willingness to consider other life sustaining therapies to treat advanced heart failure, such as ventilation, dialysis or a feeding tube. Among the patients identified as high risk by physicians, 77 percent were willing to consider LVAD, but 63 percent indicated they would decline other simpler life sustaining therapies.
"More than likely, these inconsistencies indicate a poor understanding of these treatment options," Ambardekar said. "Patients may not fully appreciate the invasive nature of some of these procedures, so we probably need to look for better ways to educate our patients both on the severity of their disease and their treatment options—well before they need these advanced therapies."
"This work highlights the importance of increasing the educational awareness of our patients and the need for more research in this area," said Christopher M. O'Connor, MD, FACC, editor-in-chief of JACC: Heart Failure.
Study limitations include that the categorization of physician and patient risk, as well as the patients’ opinions on treatment options, were made at the time of enrollment. According to the researchers, it is likely that perceptions of risk and the patients' understanding of treatment options changed over the course of time.
The American College of Cardiology is the professional home for the entire cardiovascular care team. The mission of the College and its more than 52,000 members is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, offers cardiovascular accreditation to hospitals and institutions, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more, visit acc.org.
The Journal of the American College of Cardiology ranks among the top cardiovascular journals in the world for its scientific impact. JACC is the flagship for a family of journals—JACC: Cardiovascular Interventions, JACC: Cardiovascular Imaging, JACC: Heart Failure, JACC: Clinical Electrophysiology and JACC: Basic to Translational Science—that prides themselves in publishing the top peer-reviewed research on all aspects of cardiovascular disease. Learn more at JACC.org.